Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 18/20 | 0.42 |
| ▸ | BTD | P43251 | 4/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17065310 | 0.89 | GRM5 (0.45) | HRH3 | |
| SCHEMBL20702394 | 0.89 | SPR (0.38) | VNN1BTDHRH3HDAC1HDAC2 | |
| SCHEMBL20702425 | 0.89 | SPR (0.38) | VNN1BTDHRH3HDAC1HDAC2 | |
| SCHEMBL20702405 | 0.89 | SPR (0.38) | VNN1BTDHRH3HDAC1HDAC2 | |
| SCHEMBL20702446 | 0.88 | USP2 (0.40) | VNN1BTD | |
| SCHEMBL18517457 | 0.85 | VNN1 (0.38) | VNN1BTDHRH3HDAC1HDAC2 | |
| SCHEMBL29418104 | 0.85 | HSD11B1 (0.42) | — | |
| SCHEMBL19779297 | 0.82 | SMN1; SMN2 (0.50) | VNN1BTDHRH3 | |
| SCHEMBL20702381 | 0.82 | HDAC1 (0.42) | VNN1BTDHRH3HDAC1HDAC2 | |
| SCHEMBL16600607 | 0.82 | VNN1 (0.41) | VNN1BTDHRH3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344623-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | DOMAIN THERAPEUTICS SA (FR) | 2025-07-01 | — | — | US | claimed |
| EP-3914600-B1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2024-08-07 | — | — | EP | claimed |
| EP-3661941-B1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | claimed |
| US-20220119412-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-04-21 | — | — | US | claimed |
| US-11186592-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2021-11-30 | — | — | US | claimed |
| US-20200181171-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-06-11 | — | — | US | claimed |
| EP-3661941-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-06-10 | — | — | EP | claimed |
| WO-2019025099-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-07 | — | — | WO | claimed |
| US-12344623-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | DOMAIN THERAPEUTICS SA (FR) | 2025-07-01 | — | — | US | disclosed |
| US-20240279338-A1 | Combination Treatment of Cancer | ARES TRADING SA (CH) | 2024-08-22 | — | — | US | disclosed |
| EP-3914600-B1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2024-08-07 | — | — | EP | disclosed |
| CN-118056834-A | Fused ring pyridone derivatives, preparation method and application thereof | 合肥医工医药股份有限公司 | 2024-05-21 | — | — | CN | disclosed |
| WO-2024028273-A1 | NOVEL CRYSTALLINE FORMS OF (S)-7-OXA-2-AZA-SPIRO[4.5]DECANE-2-CARBOXYLIC ACID [7-(3,6-DIHYDRO-2H-PYRAN-4-YL)-4-METHOXY-THIAZOLO[4,5-C]PYRIDIN-2-YL]-AMIDE AND CO-CRYSTAL FORMS THEREOF | MERCK PATENT GMBH (DE) | 2024-02-08 | — | — | WO | disclosed |
| EP-3661941-B1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | disclosed |
| US-20220119412-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-04-21 | — | — | US | disclosed |
| US-11186592-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2021-11-30 | — | — | US | disclosed |
| US-20200181171-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-06-11 | — | — | US | disclosed |
| EP-3661941-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019025099-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-07 | — | — | WO | disclosed |
| WO-2000027790-A1 | MUTILIN COMPOUNDS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344623-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | VNN1 3377/4885BTD 2737/4885HRH3 482/4885 |
| US-11186592-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | ADORA1, ADORA2A, AMPD2 | VNN1 3614/4885BTD 2788/4885HRH3 733/4885 |
| US-20240279338-A1 | Combination Treatment of Cancer | CD274, PDCD1, ENTPD1 | VNN1 2870/4885BTD 2472/4885HRH3 922/4885 |
| US-20200181171-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, AMPD2 | VNN1 3614/4885BTD 2788/4885HRH3 733/4885 |
| US-20220119412-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | VNN1 3377/4885BTD 2737/4885HRH3 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.